88 related articles for article (PubMed ID: 6464401)
1. [Mononuclear cell reactions in the combined treatment of patients with a cutaneous melanoblastoma of the lower extremities].
Turkina NV; Freĭdlin IS; Chetvertakova LV; Levin AO; Andrianov IG
Vopr Onkol; 1984; 30(7):45-50. PubMed ID: 6464401
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors and improving treatment of cutaneous melanoma].
Vihinen P; Kähäri VM; Pyrhönen S
Duodecim; 2004; 120(12):1445-56. PubMed ID: 15293705
[No Abstract] [Full Text] [Related]
5. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
6. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
7. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
8. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
9. Melanoma in the elderly patient: relevance of the aging immune system.
Hegde UP; Chakraborty N; Kerr P; Grant-Kels JM
Clin Dermatol; 2009; 27(6):537-44. PubMed ID: 19880041
[TBL] [Abstract][Full Text] [Related]
10. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
11. [Gender, tumor localization and regional metastases as prognostic factors in combined and complex treatment of cutaneous melanoma].
Kudriavtsev DV; Mardynskiĭ IuS; Kudriavtseva GT
Vopr Onkol; 2007; 53(2):170-4. PubMed ID: 17663170
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of malignant melanoma of the skin (a lecture)].
Denisov LE; Kurdina MI
Khirurgiia (Mosk); 1996; (1):17-22. PubMed ID: 8683912
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma.
Califano J; Nance M
Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
15. [Evidence for tumor immunity in human malignant melanoma].
Nagel GA
Schweiz Med Wochenschr; 1970 Jun; 100(23):995-1000. PubMed ID: 4947017
[No Abstract] [Full Text] [Related]
16. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
17. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis.
Spillane AJ; Saw RP; Tucker M; Byth K; Thompson JF
Ann Surg; 2008 Aug; 248(2):286-93. PubMed ID: 18650640
[TBL] [Abstract][Full Text] [Related]
18. Xenovaccinotherapy for melanoma.
Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
20. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
